Breckenridge Pharmaceutical, the US subsidiary of Towa International that markets, distributes, and sells generic medicines in the US, has announced a new partnership with Maiva Pharma, focused on sterile injectable products to be supplied primarily to hospitals and clinics.
The collaboration strengthens Breckenridge’s position as a reliable supplier to the US hospital market, with Maiva serving as a key manufacturing partner for several injectable products.
Brian Guy, President and Chief Commercial Officer of Breckenridge, said: ‘Ensuring consistent access to critical care injectables is key for our mission and for the needs of the US hospital community. This collaboration strengthens our growing presence in the hospital channel and reinforces our commitment to expanding patient access to high-quality, affordable medicines. It also represents a significant milestone in Breckenridge’s evolution into three clearly defined patient-focused business lines, specialty, hospital, and retail, allowing us to better serve patients while providing healthcare providers with reliable and cost-effective treatment options.’
This partnership reflects Breckenridge’s ongoing investment in the dynamic hospital pharmaceutical supply chain.
By partnering with Maiva, an organization with expertise in sterile injectable manufacturing, Breckenridge is expanding its capacity to support hospitals nationwide and strengthen the availability of critical medications.
